Reuters: Health
Swiss drugmaker Novartis on Monday said it is jettisoning what it had hoped would be a billion-dollar-selling asthma drug, fevipiprant, from its development program after the medicine failed another set of key trials.
Novartis drops asthma drug fevipiprant after trial failures
Novartis drops asthma drug fevipiprant after trial failures
Reuters: Health
Swiss drugmaker Novartis on Monday said it is jettisoning what it had hoped would be a billion-dollar-selling asthma drug, fevipiprant, from its development program after the medicine failed another set of key trials.
Reuters: Health
Swiss drugmaker Novartis on Monday said it is jettisoning what it had hoped would be a billion-dollar-selling asthma drug, fevipiprant, from its development program after the medicine failed another set of key trials.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment